New Alzheimer's drug VY7523 enters human safety trials
Disease control
Ongoing
This study is testing a new medicine called VY7523 in 52 people with early Alzheimer's disease. The goal is to see if the drug is safe and how it works in the brain. Some participants will get the drug, others a placebo, and the study lasts up to 12 months for the highest dose gr…
Phase: PHASE1, PHASE2 • Sponsor: Voyager Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC